Key Drivers
- Strong margins
- High SG&A
- Solid liquidity
AIAI Summary
Bio‑Rad should now be valued and traded as a capital‑efficient, cash‑generation play rather than a steady high‑growth instrument story, so investors should prioritize management's capital allocation (buybacks/M&A) and margin recovery over top‑line optimism. The primary near‑term risk to that thesis is persistent instrument demand cyclicality and China reimbursement headwinds—monitor quarterly instrument orders, working‑capital trends, and ddPCR commercialization uptake as the actionable catalysts for re‑rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •High SG&A
- •Solid liquidity
BIO delivers strong profitability and cash generation with conservative leverage (FY25 net margin 29%, FCF $374.7M) but earnings are highly sensitive to very high operating/SG&A costs and large non-cash/investment balances that require scrutiny.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Defended support
- •Resistance cap
Over the last month BIO has a modest short-term downtrend (≈‑2.5%) trading in a defended low‑$260s support band but blocked by resistance in the high‑$270s–mid‑$280s, leaving it range‑bound until a decisive break below $261 or above ~$280–$285.
~8–9% intraperiod range between $284.68 and $261.24 indicating moderate volatility
Sentiment & News
Key News Insights:
- •Investor outreach
- •Commercial partnerships
- •Minor rebalancing
Small- to mid-cap BIO-related companies showcased investor outreach and commercial traction via conference presentations and partnerships, while an institutional holder modestly trimmed a Bio-Rad stake, signaling continued business development with limited material corporate changes.
Overall, these developments should modestly support sentiment and partnership-driven revenue prospects for smaller BIO names while having limited near-term impact on larger-cap valuations
Similar Companies in Healthcare
Other companies in the same sector with AI ratings